2025-12-17 - Analysis Report
Okay, here's a breakdown and analysis of the provided data for Recursion Pharmaceuticals Inc. (RXRX), structured as requested:

**0) Report Summary**

*   **RXRX vs. S&P 500 (VOO):** RXRX has significantly underperformed the S&P 500.
*   **Recent Performance:** Stock price is hovering around its 20-day SMA.
*   **Market Risk Indicator:** Signals medium investment risk.
*   **Analyst Sentiment:** Neutral.
*   **Financials:** Low revenue and negative profit margins.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to discover, develop and commercialize therapeutics that radically improve lives.
*   **Cumulative Return:**
    *   RXRX: -31.99%
    *   VOO (S&P 500): 41.79%
*   **Divergence:** -67.1 (Relative Divergence: 4.2)
*   **Analysis of Alpha, Beta, CAGR, and MDD:**

    | Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
    |------------|-------|-------|-------|------|--------|
    | 2021-2023  | 22.0% | 81.0% | 26.0% | -0.2 | 5.1    |
    | 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1  | 3.5    |
    | 2023-2025  | 10.0% | 80.0% | -54.0% | 0.1  | 2.2    |

    *   **CAGR:** The Compound Annual Growth Rate has decreased over the time periods analyzed, indicating slowing growth.
    *   **MDD:** The Maximum Drawdown remains extremely high (around 80-81%), indicating significant volatility and potential for large losses.
    *   **Alpha:** The Alpha has drastically declined from a positive 26% (2021-2023) to a negative -54% (2023-2025).  This indicates a significant *underperformance* relative to the benchmark (S&P 500), and the company is losing its ability to generate excess returns.
    *   **Beta:** The Beta values are low, close to zero. This suggests that RXRX's price movements are not strongly correlated with the overall market (S&P 500). In other words, RXRX has been independent of the fluctuations in the S&P500.

    *   **Cap(B):** The Market Capitalization of Recursion Pharmaceuticals has decreased over the time periods analyzed, indicating a decline in investor confidence.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 4.2
*   **Price Change:** Unchanged (0.0) from previous close.
*   **Simple Moving Averages (SMA):**
    *   5-day SMA: 4.416
    *   20-day SMA: 4.4308
    *   60-day SMA: 5.0403
*   **Analysis:** The price is below all SMAs, and all SMAs are trending downwards.  The 5-day and 20-day SMAs are close together, while the 60-day SMA is significantly higher. This suggests a continuing downward trend.

**3) RSI, PPO, MRI, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Risk)
*   **RSI:** 44.72 (Neutral - not overbought or oversold)
*   **PPO:** -0.0635 (Slightly negative - suggesting a potential downward trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** +0.4 (Short-term increase/rise)
*   **Expected Return:** -118.7% (Highly negative - suggesting a very poor long-term investment prospect compared to the S&P 500)
*   **Analysis:**
    *   The MRI indicates a medium level of risk, suggesting that while not extremely risky, caution is warranted.
    *   The RSI suggests the stock is neither overbought nor oversold.
    *   The significantly negative Expected Return is a major red flag, indicating a large potential loss compared to the S&P 500 if held long-term.

**4) Recent News & Significant Events**

*   **Key Themes:**
    *   **Valuation & CEO:** Discussion of valuation following a new CEO, narrowed losses, and a milestone partnership payment.
    *   **Exscientia Merger & Clinical Data:** Speculation and opinions on a potential merger and clinical data readouts.
    *   **Analyst Sentiment:** A consensus "Hold" rating from brokerages.
    *   **Share Registration:** Questions about whether share registration signals deepening tech partnerships or a shift in strategy.
    *   **Insider Selling:** Reports of insider selling and a CEO transition.
    *   **Meme Stock?:** A question about whether RXRX could be considered a meme stock.
*   **Analysis:**
    *   The news is mixed. The narrowed losses and partnership payment are positive.
    *   The "Hold" rating and concerns about strategy suggest caution.
    *   Insider selling is often seen as a negative signal.
    *   The mention of "meme stock" suggests the stock's price might be influenced by social media sentiment rather than fundamentals.

**4-2) Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.62 (~Hold)
*   **Opinions:** 7
*   **Target Price:**
    *   Average: $7.00
    *   High: $11.00
    *   Low: $3.00
*   **Recent Rating Changes:**  No specific changes listed.
*   **Analysis:**  The analyst consensus is neutral ("Hold"). The wide range between the high and low target prices suggests uncertainty about the stock's future. The absence of recent rating changes implies stability (or lack of significant movement) in analyst sentiment.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-11-05 | -0.36 | 0.01 B$      |
| 2025-08-05 | -0.41 | 0.02 B$      |
| 2025-05-05 | -0.5  | 0.01 B$      |
| 2024-11-06 | -0.34 | 0.03 B$      |
| 2025-11-05 | -0.34 | 0.03 B$      |

*   **Analysis:** The company is consistently losing money (negative EPS).  Revenue is low and inconsistent. While there may have been slight improvements to EPS, they haven't translated into profitability. This data shows a weak earnings profile.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.00B    | -194.74%      |
| 2025-06-30   | $0.02B    | -5.54%       |
| 2025-03-31   | $0.01B    | -47.31%       |
| 2024-12-31   | $0.00B    | -183.62%      |
| 2024-09-30   | $0.03B    | 53.69%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-09-30   | $1.05B   | -15.50%  |
| 2025-06-30   | $0.92B   | -18.70%  |
| 2025-03-31   | $0.93B   | -21.68%  |
| 2024-12-31   | $1.03B   | -17.29%  |
| 2024-09-30   | $0.52B   | -18.27%  |

*   **Analysis:**
    *   Revenue is very low and fluctuates.
    *   Profit margins are mostly negative, indicating the company is spending far more than it is earning. The one positive profit margin in 2024-09-30 could be associated with milestone payments.
    *   Equity has seen some fluctuations but is above $1B for much of the time period.
    *   Return on Equity (ROE) is consistently negative, demonstrating an inability to generate profit from shareholder equity.

**7) Comprehensive Analysis (Summary)**

Recursion Pharmaceuticals (RXRX) presents a high-risk investment profile. It has significantly underperformed the S&P 500, faces high volatility, and has a negative expected return. Recent news highlights both potential catalysts (new CEO, partnership payments) and concerns (insider selling, strategy questions). Analyst sentiment is neutral. The financial data is concerning: low and inconsistent revenue, negative profit margins, and negative ROE. While the company has a substantial amount of equity, it's not generating profits. In conclusion, based on the provided data, investing in RXRX appears very risky. The potential for large losses outweighs the potential gains, at least in the short to medium term.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.